Cargando…

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study

BACKGROUND: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation. The prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho de Oliveira, Caroline Cândida, Agati, Leandro Barile, Ribeiro, Camilla Moreira, Resende Aguiar, Valéria Cristina, Caffaro, Roberto Augusto, da Silva Santos, Marisa, Alves Fernandes, Ricardo Ribeiro, Alberto da Silva Magliano, Carlos, Tafur, Alfonso, Spyropoulos, Alex C., Lopes, Renato Delascio, Fareed, Jawed, Ramacciotti, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288203/ https://www.ncbi.nlm.nih.gov/pubmed/37366432 http://dx.doi.org/10.1016/j.lana.2023.100543

Ejemplares similares

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
por: Qneibi, Dalia, et al.
Publicado: (2020)

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial()
por: Ramacciotti, Eduardo, et al.
Publicado: (2021)

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?
por: Ramacciotti, Eduardo, et al.
Publicado: (2019)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)

Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020
por: Ramacciotti, Eduardo, et al.
Publicado: (2020)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
por: Bonifácio, Lívia Pimenta, et al.
Publicado: (2023)

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide
por: Ramacciotti, Eduardo, et al.
Publicado: (2018)

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
por: Fareed, Jawed, et al.
Publicado: (2019)

A Prospective Study Evaluating Patterns of Responses to the Caprini Score to Prevent Venous Thromboembolism After Interventional Treatment for Varicose Veins
por: Grill, Marcelo Halfen, et al.
Publicado: (2022)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement
por: Tafur, Alfonso, et al.
Publicado: (2019)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
por: MacDougall, Kira, et al.
Publicado: (2020)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Zika and Chikungunya Virus and Risk for Venous Thromboembolism
por: Ramacciotti, Eduardo, et al.
Publicado: (2019)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study
por: Lenci Marques, Gustavo, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial
por: Kröll, Dino, et al.
Publicado: (2023)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Comparison of thromboprophylaxis patterns in arthroplasty in public and private hospitals
por: Cortada, Aline Pinheiro dos Santos, et al.
Publicado: (2015)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
por: Willmann, Stefan, et al.
Publicado: (2022)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Thromboprophylaxis in lower limb varicose vein surgery in Brazil
por: Ribeiro, Alcides José Araújo, et al.
Publicado: (2022)

Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials
por: Ning, Guang-Zhi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a8em35q83mhbpes2678nplf6of